Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
31 Octubre 2023 - 5:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report its third quarter 2023
financial results on Tuesday, November 7, 2023 and will provide a
business update.
Altimmune management will host a conference call
at 8:30 am E.T. on November 7 to discuss financial results and
provide a business update. The conference call will be webcast live
on Altimmune’s Investor Relations website at
https://ir.altimmune.com/investors.
Participants who would like to join the call may
register here to receive the dial-in numbers and unique PIN to
access the call. Shortly after the call, a replay will be available
on the Investor Relations website for up to three months.
About AltimmuneAltimmune is a
clinical-stage biopharmaceutical company focused on developing
innovative next-generation therapeutics for the treatment of
obesity and liver diseases. The Company’s lead product candidate,
pemvidutide, is a GLP-1/glucagon dual receptor agonist that is
being developed for the treatment of obesity and NASH. In addition,
Altimmune is developing HepTcell™, an immunotherapeutic designed to
achieve a functional cure for chronic hepatitis B. For more
information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor Contact:Richard
EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Media Contact:Danielle
CanteyEvoke CanalePhone:
619-826-4657danielle.cantey@evokegroup.com
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De May 2023 a May 2024